HUE046564T2 - XI-es faktor elleni monoklonális antitestek és eljárások az alkalmazásukra - Google Patents

XI-es faktor elleni monoklonális antitestek és eljárások az alkalmazásukra

Info

Publication number
HUE046564T2
HUE046564T2 HUE15189714A HUE15189714A HUE046564T2 HU E046564 T2 HUE046564 T2 HU E046564T2 HU E15189714 A HUE15189714 A HU E15189714A HU E15189714 A HUE15189714 A HU E15189714A HU E046564 T2 HUE046564 T2 HU E046564T2
Authority
HU
Hungary
Prior art keywords
factor
methods
monoclonal antibodies
monoclonal
antibodies
Prior art date
Application number
HUE15189714A
Other languages
English (en)
Inventor
Andras Gruber
Erik Tucker
Stephen Hanson
David Gailani
Original Assignee
Univ Oregon Health & Science
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40568500&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE046564(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Oregon Health & Science, Univ Vanderbilt filed Critical Univ Oregon Health & Science
Publication of HUE046564T2 publication Critical patent/HUE046564T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
HUE15189714A 2007-11-21 2008-11-21 XI-es faktor elleni monoklonális antitestek és eljárások az alkalmazásukra HUE046564T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98952307P 2007-11-21 2007-11-21

Publications (1)

Publication Number Publication Date
HUE046564T2 true HUE046564T2 (hu) 2020-03-30

Family

ID=40568500

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15189714A HUE046564T2 (hu) 2007-11-21 2008-11-21 XI-es faktor elleni monoklonális antitestek és eljárások az alkalmazásukra

Country Status (16)

Country Link
US (7) US8236316B2 (hu)
EP (2) EP3002298B1 (hu)
JP (1) JP2011504371A (hu)
AU (1) AU2008326348B2 (hu)
CA (1) CA2705851C (hu)
CY (1) CY1122270T1 (hu)
DK (2) DK2222707T3 (hu)
ES (2) ES2566963T3 (hu)
HK (1) HK1223114A1 (hu)
HR (1) HRP20191999T1 (hu)
HU (1) HUE046564T2 (hu)
LT (1) LT3002298T (hu)
PL (1) PL3002298T3 (hu)
PT (1) PT3002298T (hu)
SI (1) SI3002298T1 (hu)
WO (1) WO2009067660A2 (hu)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3002298B1 (en) * 2007-11-21 2019-08-28 Oregon Health & Science University Anti-factor xi monoclonal antibodies and methods of use thereof
EP2297207B1 (en) * 2008-06-19 2018-10-03 Prothix BV Use of anti-factor xi antibodies for prevention or treatment of thrombus formation
KR101979134B1 (ko) 2008-10-15 2019-05-15 아이오니스 파마수티컬즈, 인코포레이티드 인자 １１ 발현의 조정
PL2373691T3 (pl) 2008-12-18 2019-07-31 Oregon Health & Science University PRZECIWCIAŁA ANTY-fXI I SPOSOBY ZASTOSOWANIA
AU2010236286B2 (en) * 2009-04-15 2013-06-06 Isis Pharmaceuticals, Inc. Modulation of inflammatory responses by Factor XI
NZ702494A (en) * 2010-03-01 2016-09-30 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
EP2497489A1 (en) * 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
US9352016B2 (en) 2011-03-09 2016-05-31 Csl Behring Gmbh Factor XII inhibitors for the administration with medical procedures comprising contact with artificial surfaces
SI2847228T1 (sl) * 2012-05-10 2018-11-30 Bayer Pharma Aktiengesellschaft Protitelesa zmožna vezave na faktor koagulacije XI in/ali njeno aktivirano obliko faktor XIa in njihove uporabe
WO2014089493A1 (en) 2012-12-07 2014-06-12 Vanderbilt University Antibodies against factor xii and uses thereof
US20140220552A1 (en) * 2013-02-01 2014-08-07 Becton, Dickinson And Company Blood collection devices containing contact pathway inhibition additives
US10286047B2 (en) 2013-03-08 2019-05-14 Csl Behring Gmbh Treatment and prevention of remote ischemia-reperfusion injury
DK3177642T3 (da) 2014-08-07 2022-02-21 Novartis Ag Angiopoietin-lignende 4-antistoffer og fremgangsmåder til anvendelse deraf
WO2016020882A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use
JOP20200312A1 (ar) * 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
CA3025896A1 (en) 2015-07-23 2017-01-26 The Regents Of The University Of California Antibodies to coagulation factor xia and uses thereof
MA43660A (fr) 2016-01-22 2018-11-28 Adimab Llc Anticorps anti-facteur xi de coagulation
AU2017236063A1 (en) * 2016-03-23 2018-10-11 Prothix Bv Monoclonal antibodies against the active site of factor XI and uses thereof
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
KR102379580B1 (ko) * 2016-06-14 2022-03-29 머크 샤프 앤드 돔 코포레이션 항응고 인자 xi 항체
EP3293593B1 (en) * 2016-09-12 2019-03-20 Sandvik Intellectual Property AB Method for estimating error propagation
AU2017329645A1 (en) * 2016-09-20 2019-04-04 Aronora Inc. Novel antibodies against factor XI and uses thereof
IL267538B1 (en) * 2016-12-23 2024-01-01 Novartis Ag Antibodies against factor XI and methods for use in preventing, treating, managing or reducing the risk of thromboembolic disorder or stroke in a patient
KR20190099256A (ko) * 2016-12-23 2019-08-26 노파르티스 아게 항-인자 XI/XIa 항체를 사용한 치료 방법
CN108409863B (zh) * 2017-02-10 2023-09-26 上海仁会生物制药股份有限公司 抗凝血因子xi抗体
US11958911B2 (en) 2017-02-10 2024-04-16 Shanghai Benemae Pharmaceutical Anti-coagulation factor XI antibody
AU2018372135A1 (en) 2017-11-22 2020-05-28 Novartis Ag Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof
US11155638B2 (en) 2018-05-08 2021-10-26 Rhode Island Hospital Anti-CHI3L1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatonhepatitis and subsequent complications
EP3799604A4 (en) 2018-05-09 2022-09-07 Ionis Pharmaceuticals, Inc. COMPOUNDS AND METHODS FOR REDUCING FXI EXPRESSION
MX2021001613A (es) * 2018-08-09 2021-04-28 Shanghai Benemae Pharmaceutical Corp Anticuerpos anti-factor xi.
KR20230035079A (ko) * 2020-07-03 2023-03-10 수조우 알파맵 씨오., 엘티디. 응고인자 xi(fxi) 결합 단백질

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
EP0216846B2 (en) 1985-04-01 1995-04-26 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
WO1989012624A2 (en) 1988-06-14 1989-12-28 Cetus Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
ZA902949B (en) 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
DE69127749T2 (de) 1990-03-20 1998-04-16 Univ Columbia Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region
WO1992008495A1 (en) 1990-11-09 1992-05-29 Abbott Biotech, Inc. Cytokine immunoconjugates
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US20030235587A1 (en) * 1998-08-07 2003-12-25 Feuerstein Giora Z. Anticoagulant agents useful in treatment of thrombosis
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6623960B1 (en) * 1999-02-12 2003-09-23 The United States Of America As Represented By The Department Of Health And Human Services Agents that bind to and inhibit human cytochrome P450 2C8, 2C9, 2C18 and 2C19
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
CN101134107A (zh) * 2000-05-15 2008-03-05 史密丝克莱恩比彻姆公司 抗血栓剂
CA2429544C (en) 2000-11-17 2010-10-19 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
US7319139B2 (en) 2001-01-29 2008-01-15 Biogen Idec, Inc. TAG-72 specific CH2 domain deleted antibodies
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20080138837A1 (en) * 2004-07-19 2008-06-12 Robert Greenfield Methods and kits for detecting and measuring ADAMTS13/FXI complexes
EP2465872A3 (en) * 2004-10-25 2012-12-19 Merck Sharp & Dohme Corporation Anti-ADDL antibodies and uses thereof
US7859456B2 (en) 2006-10-10 2010-12-28 Sirf Technology Holdings, Inc. Method of mixed data assisted and non data assisted navigation signal acquisition, tracking and reacquisition
EP2152750A1 (en) * 2007-04-23 2010-02-17 Schering Corporation Anti-mdl-1 antibodies
EP3002298B1 (en) * 2007-11-21 2019-08-28 Oregon Health & Science University Anti-factor xi monoclonal antibodies and methods of use thereof
EP2297207B1 (en) 2008-06-19 2018-10-03 Prothix BV Use of anti-factor xi antibodies for prevention or treatment of thrombus formation
JP5501369B2 (ja) 2008-11-25 2014-05-21 メルク・シャープ・アンド・ドーム・コーポレーション 可溶性グアニレートシクラーゼ活性化剤
CN103096718B (zh) 2010-05-27 2016-01-20 默沙东公司 可溶性鸟苷酸环化酶活化剂
EP2585055A1 (de) 2010-06-25 2013-05-01 Bayer Intellectual Property GmbH Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen
EP2590979A1 (de) 2010-07-09 2013-05-15 Bayer Intellectual Property GmbH Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
ES2583086T3 (es) 2011-04-21 2016-09-19 Bayer Intellectual Property Gmbh Pirazolopiridinas sustituidas con fluoroalquilo y su uso
CA2834901A1 (en) 2011-05-06 2012-11-15 Bayer Intellectual Property Gmbh Substituted imidazopyridines and imidazopyridazines and the use thereof
MX359032B (es) 2011-09-01 2018-09-12 Hoffmann La Roche Inhibidores de pirrolopirazina cinasa.
SG11201400083VA (en) 2011-09-02 2014-06-27 Bayer Ip Gmbh Substituted annellated pyrimidine and the use thereof
SI2847228T1 (sl) 2012-05-10 2018-11-30 Bayer Pharma Aktiengesellschaft Protitelesa zmožna vezave na faktor koagulacije XI in/ali njeno aktivirano obliko faktor XIa in njihove uporabe

Also Published As

Publication number Publication date
CY1122270T1 (el) 2020-11-25
US20150322163A1 (en) 2015-11-12
ES2566963T3 (es) 2016-04-18
LT3002298T (lt) 2019-12-10
WO2009067660A3 (en) 2009-07-09
US9636399B2 (en) 2017-05-02
HK1223114A1 (zh) 2017-07-21
US20110020349A1 (en) 2011-01-27
AU2008326348A1 (en) 2009-05-28
WO2009067660A2 (en) 2009-05-28
US8236316B2 (en) 2012-08-07
EP2222707B1 (en) 2016-01-06
AU2008326348B2 (en) 2014-01-30
DK2222707T3 (en) 2016-04-11
US10577428B2 (en) 2020-03-03
ES2755376T3 (es) 2020-04-22
US8399648B2 (en) 2013-03-19
JP2011504371A (ja) 2011-02-10
CA2705851A1 (en) 2009-05-28
PL3002298T3 (pl) 2020-03-31
US20130171144A1 (en) 2013-07-04
US20180355057A1 (en) 2018-12-13
PT3002298T (pt) 2019-11-20
US20170204195A1 (en) 2017-07-20
SI3002298T1 (sl) 2019-12-31
US20120276112A1 (en) 2012-11-01
EP3002298B1 (en) 2019-08-28
US20140322219A1 (en) 2014-10-30
DK3002298T3 (da) 2019-10-28
EP2222707A2 (en) 2010-09-01
HRP20191999T1 (hr) 2020-02-07
CA2705851C (en) 2016-11-01
US9125895B2 (en) 2015-09-08
EP3002298A1 (en) 2016-04-06

Similar Documents

Publication Publication Date Title
HK1223114A1 (zh) 抗因子 單克隆抗體及其使用方法
IL266039A (en) Anti-factor D antibodies of human origin and their uses
HRP20181969T1 (hr) Humanizirana protutijela protiv čimbenika d i njihova upotreba
HK1199047A1 (en) Il-31 monoclonal antibodies and methods of use il-31
EP2021029A4 (en) HUMANIZED FC RIB SPECIFIC ANTIBODIES AND METHOD FOR THEIR USE
IL195573A0 (en) Fc??RIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
EP2347038A4 (en) METHOD FOR HUMANIZATION AND AFFINITY TREATMENT OF ANTIBODIES
IL200610A0 (en) Human monoclonal anti-ip-10 antibodies and uses thereof
HUE042940T2 (hu) Anti-FXI antitestek és alkalmazási eljárások
EP2185719A4 (en) RANTES ANTIBODIES AND METHOD FOR THEIR USE
IL211623A0 (en) Anti-notch2 antibodies and methods of use
EP2048162A4 (en) NEW MONOCLONAL ANTIBODY AND ITS USE
HK1158977A1 (zh) 抗膜鐵轉運蛋白 單克隆抗體及其用途